Cypher Revenue Stream Counters Some DES Damage To Guidant Stent Sales
This article was originally published in The Gray Sheet
Executive Summary
Guidant's co-promotion and catheter supply agreements with Cordis generated revenue of $21 mil. in Q1, slightly assuaging the impact of drug-eluting stents on bare-metal sales
You may also be interested in...
Boston Scientific, Guidant Close The Deal Following FTC Approval
Boston Scientific closed its $28 bil. acquisition of Guidant on April 21, one day after the Federal Trade Commission approved the deal - the largest medical device acquisition in history
Boston Scientific, Guidant Close The Deal Following FTC Approval
Boston Scientific closed its $28 bil. acquisition of Guidant on April 21, one day after the Federal Trade Commission approved the deal - the largest medical device acquisition in history
Guidant Awaits SPIRIT Trial Data For Clear Vision Of Future Stent Business
Feasibility data on the Multi-Link Vision cobalt-chromium, durable-polymer, everolimus-eluting stent will be key to predicting the stability of Guidant's DES technology platform in the post-Dollens era